BiotechTubeBiotechTube
Home/Pliant Therapeutics/Hans Hull, M.Sc.
HH

Hans Hull, M.Sc.

Chief Commercial Officer

Pliant Therapeutics

Therapeutic Areas

Fibrotic DiseasesPulmonaryHepatologyOncology

Pliant Therapeutics Pipeline

DrugIndicationPhase
Bexotegrast (PLN-74809)Idiopathic Pulmonary Fibrosis (IPF)Phase 2b
PLN-101095Advanced Solid TumorsPhase 1
PLN-101325Undisclosed Fibrotic IndicationPreclinical
Muscular Dystrophy ProgramMuscular DystrophyDiscovery

Leadership Team at Pliant Therapeutics

ÉL
Éric Lefebvre, M.D.
Chief Executive Officer
KC
Keith Cummings, M.D.
Chief Financial Officer
BC
Bernard Coulie, M.D., Ph.D.
President and Chief Executive Officer
ÉL
Éric Lefebvre, M.D.
Chief Medical Officer
JP
John P. McLaughlin
Chief Business Officer
X(
Xiaokui (Kevin) Zhang, Ph.D.
Chief Scientific Officer
LC
Lily Cheung, Ph.D.
Senior Vice President, Regulatory Affairs & Quality Assurance
RJ
Robert J. Benschop, Ph.D.
Senior Vice President, Research & Non-Clinical Development
JG
John G. M. Lee, J.D.
Senior Vice President, General Counsel & Corporate Secretary
GG
Gary G. Gysin
Board Member
View full Pliant Therapeutics profile